In a groundbreaking retrospective study published in BMC Cancer, researchers have unveiled compelling evidence supporting the pivotal role of chemotherapy in managing isolated neck lymphatic metastasis (NLNM) among patients suffering from advanced epithelial ovarian cancer (EOC). This study meticulously analyzes clinical outcomes, revealing insights into treatment responses and survival rates for those grappling with FIGO stage IV EOC complicated by isolated NLNM—a scenario that has long posed complex therapeutic challenges.
Epithelial ovarian cancer, notorious for its late-stage diagnosis and aggressive metastatic patterns, often portends a grim prognosis when lymphatic dissemination extends beyond the peritoneal cavity. Notably, the occurrence of isolated neck lymph node metastases, although relatively rare, signifies a unique metastatic pathway that necessitates targeted investigation. The current study delves into the specifics of chemotherapy efficacy against such metastases, thus filling a critical knowledge gap in oncological management.
Between December 2014 and November 2021, the clinical trajectories of 24 patients diagnosed with stage IV EOC exhibiting isolated NLNM were meticulously reviewed. These participants underwent diverse therapeutic interventions including primary debulking surgery (PDS), neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS), and chemotherapy monotherapy. From this cohort, a majority received NACT plus IDS, highlighting prevailing clinical preferences in managing extensive disease burdens.
.adsslot_QwjZMp3eGW{width:728px !important;height:90px !important;}
@media(max-width:1199px){ .adsslot_QwjZMp3eGW{width:468px !important;height:60px !important;}
}
@media(max-width:767px){ .adsslot_QwjZMp3eGW{width:320px !important;height:50px !important;}
}
ADVERTISEMENT
Strikingly, only a minority (8.3%) underwent PDS, reflecting either surgical inoperability or strategic treatment sequencing favoring systemic chemotherapy ahead of surgical intervention. The preference for preoperative chemotherapy underscores its role in reducing tumor load and enhancing cytoreduction outcomes—a foundational principle in advanced ovarian cancer treatment paradigms.
Surgical outcomes revealed that just over half of the patients (54.2%) achieved optimal abdominal cytoreduction, classified as R0 resection—indicating no gross residual disease. The remainder had residual macroscopic tumor burden (R1/R2 resection). This differentiation is crucial, given the established relationship between cytoreduction completeness and patient survival, particularly in advanced EOC cases.
Chemotherapy responses of the NLNMs themselves were noteworthy. Approximately one-third of patients experienced complete remission within the neck lymph nodes, while nearly two-thirds achieved partial remission. One patient maintained stable disease, and notably, none required direct surgical excision or radiotherapy targeting the metastatic cervical lymph nodes. This suggests systemic chemotherapy’s efficacy in controlling lymphatic spread without adjunct local therapies.
Recurrence patterns also yielded intriguing findings. While over 60% experienced disease relapse, cervical lymph node recurrence was rare, documented in only two patients. This low rate of lymphatic relapse post-chemotherapy further supports systemic treatment sufficiency in controlling neck nodal disease, potentially sparing patients from additional invasive procedures.
Survival analysis established a median progression-free survival (PFS) of 35 months and an overall survival (OS) of 48 months for the entire cohort—a promising prognosis given the traditionally poor outcomes associated with stage IV EOC. Importantly, patients who underwent R0 abdominal debulking demonstrated significantly prolonged PFS and OS compared to those with residual disease post-surgery, emphasizing the critical role of surgical cytoreduction in multimodal treatment.
Intriguingly, patients who developed lymphatic recurrence post-treatment exhibited better overall survival compared to those whose disease recurred within the abdomen or distantly. This phenomenon may reflect inherent biological differences in tumor spread or therapeutic susceptibility within lymphatic versus visceral sites, opening avenues for further oncological research.
The absence of localized treatments such as neck lymph node resection or radiotherapy in this patient population challenges conventional approaches and suggests that chemotherapy alone can adequately manage isolated NLNM. Such findings could reshape clinical guidelines, minimizing treatment-related morbidity while ensuring efficacy.
This study also underscores the significance of aggressive abdominal disease control via surgery as a cornerstone in managing advanced stage EOC with atypical metastatic patterns. The interplay between systemic chemotherapy and surgical cytoreduction emerges as a synergistic strategy optimizing patient outcomes.
As ovarian cancer continues to evolve as a formidable adversary in gynecological oncology, this research contributes vital data supporting tailored, less invasive approaches for select metastatic presentations. The discernment that chemotherapy can effectively neutralize cervical lymphatic metastases heralds a beacon of hope for improving quality of life and survival in affected women.
Future prospective studies and clinical trials are warranted to corroborate these retrospective findings and refine treatment protocols. Investigating molecular markers predictive of chemotherapy response in NLNM may further individualize therapy, fostering precision medicine advancements in ovarian cancer care.
In summary, the clinical efficacy analysis of chemotherapy for isolated neck lymphatic metastasis in advanced epithelial ovarian cancer highlights a paradigm shift. It affirms chemotherapy’s central role while advocating for surgical focus on abdominal disease control. These insights resonate profoundly within the oncology community, prescribing a less invasive yet potent management blueprint for a historically challenging metastatic subset.
Subject of Research: The efficacy of chemotherapy in treating isolated neck lymphatic metastasis in advanced epithelial ovarian cancer patients.
Article Title: Clinical efficacy analysis of chemotherapy of isolated neck lymphatic metastasis in advanced epithelial ovarian cancer.
Article References:
Liu, H., Luo, M., Peng, C. et al. Clinical efficacy analysis of chemotherapy of isolated neck lymphatic metastasis in advanced epithelial ovarian cancer. BMC Cancer 25, 969 (2025). https://doi.org/10.1186/s12885-025-14399-z
Image Credits: Scienmag.com
DOI: https://doi.org/10.1186/s12885-025-14399-z
Tags: advanced epithelial ovarian cancer managementchemotherapy efficacy in metastasischemotherapy in ovarian cancerclinical outcomes of chemotherapyFIGO stage IV ovarian cancerisolated NLNM in cancerneck lymph node metastasis treatmentneoadjuvant chemotherapy in ovarian canceroncological management of EOCprimary debulking surgery outcomesretrospective study on cancer treatmentsurvival rates in ovarian cancer
